Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer

Iben Kümler; Vibeke Kirk Parner; Malgorzata K Tuxen; Bjørn Skjoldbye; Magnus Bergenfeldt; Knud Mejer Nelausen; Dorte Lisbet Nielsen

doi:10.1007/s11547-014-0489-6

Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer

Iben Kümler
, Vibeke Kirk Parner
, Malgorzata K Tuxen
, Bjørn Skjoldbye
, Magnus Bergenfeldt
, Knud Mejer Nelausen
, Dorte Lisbet Nielsen

22 Citations (Scopus)

Abstract

PURPOSE: Despite improved anti-neoplastic treatment the prognosis for patients with liver metastases from metastatic breast cancer remains poor.

MATERIALS AND METHODS: Thirty-two consecutive patients with metastatic breast cancer treated with radiofrequency ablation (RFA) at the Department of Oncology, Herlev Hospital, University of Copenhagen, from 1996 to 2010.

RESULTS: Time to intrahepatic progression was median 11 months (range 1.6-184 months). Median survival after first RFA was 33.5 months. Survival at 1, 2 and 3 years was 87, 68 and 48 %, respectively. The local recurrence rate was 22 %.

CONCLUSIONS: In this small, highly selected cohort we found RFA safe and efficacious with a low local recurrence rate and a median survival above that expected with systemic treatment. Our data are in line with previous studies and underscore the need for a large prospective study using optimal chemotherapy regimens and RFA/surgery to clarify whether intense treatment protocols can prolong survival for certain patient groups.

Original language	English
Journal	La Radiologia Medica
Volume	120
Issue number	6
Pages (from-to)	536-41
Number of pages	6
ISSN	0033-8362
DOIs	https://doi.org/10.1007/s11547-014-0489-6
Publication status	Published - Jun 2015

Keywords

Adult
Aged
Aged, 80 and over
Breast Neoplasms
Catheter Ablation
Female
Follow-Up Studies
Humans
Liver Neoplasms
Middle Aged
Treatment Outcome

Access to Document

10.1007/s11547-014-0489-6

Cite this

@article{eac613cf2ffe4ebe9e0014abea39b37e,

title = "Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer",

abstract = "PURPOSE: Despite improved anti-neoplastic treatment the prognosis for patients with liver metastases from metastatic breast cancer remains poor.MATERIALS AND METHODS: Thirty-two consecutive patients with metastatic breast cancer treated with radiofrequency ablation (RFA) at the Department of Oncology, Herlev Hospital, University of Copenhagen, from 1996 to 2010.RESULTS: Time to intrahepatic progression was median 11 months (range 1.6-184 months). Median survival after first RFA was 33.5 months. Survival at 1, 2 and 3 years was 87, 68 and 48 \%, respectively. The local recurrence rate was 22 \%.CONCLUSIONS: In this small, highly selected cohort we found RFA safe and efficacious with a low local recurrence rate and a median survival above that expected with systemic treatment. Our data are in line with previous studies and underscore the need for a large prospective study using optimal chemotherapy regimens and RFA/surgery to clarify whether intense treatment protocols can prolong survival for certain patient groups.",

keywords = "Adult, Aged, Aged, 80 and over, Breast Neoplasms, Catheter Ablation, Female, Follow-Up Studies, Humans, Liver Neoplasms, Middle Aged, Treatment Outcome",

author = "Iben K{\"u}mler and \{Kirk Parner\}, Vibeke and Tuxen, \{Malgorzata K\} and Bj{\o}rn Skjoldbye and Magnus Bergenfeldt and Nelausen, \{Knud Mejer\} and Nielsen, \{Dorte Lisbet\}",

year = "2015",

month = jun,

doi = "10.1007/s11547-014-0489-6",

language = "English",

volume = "120",

pages = "536--41",

journal = "La Radiologia Medica",

issn = "0033-8362",

publisher = "Springer-Verlag Italia",

number = "6",

}

TY - JOUR

T1 - Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer

AU - Kümler, Iben

AU - Kirk Parner, Vibeke

AU - Tuxen, Malgorzata K

AU - Skjoldbye, Bjørn

AU - Bergenfeldt, Magnus

AU - Nelausen, Knud Mejer

AU - Nielsen, Dorte Lisbet

PY - 2015/6

Y1 - 2015/6

N2 - PURPOSE: Despite improved anti-neoplastic treatment the prognosis for patients with liver metastases from metastatic breast cancer remains poor.MATERIALS AND METHODS: Thirty-two consecutive patients with metastatic breast cancer treated with radiofrequency ablation (RFA) at the Department of Oncology, Herlev Hospital, University of Copenhagen, from 1996 to 2010.RESULTS: Time to intrahepatic progression was median 11 months (range 1.6-184 months). Median survival after first RFA was 33.5 months. Survival at 1, 2 and 3 years was 87, 68 and 48 %, respectively. The local recurrence rate was 22 %.CONCLUSIONS: In this small, highly selected cohort we found RFA safe and efficacious with a low local recurrence rate and a median survival above that expected with systemic treatment. Our data are in line with previous studies and underscore the need for a large prospective study using optimal chemotherapy regimens and RFA/surgery to clarify whether intense treatment protocols can prolong survival for certain patient groups.

AB - PURPOSE: Despite improved anti-neoplastic treatment the prognosis for patients with liver metastases from metastatic breast cancer remains poor.MATERIALS AND METHODS: Thirty-two consecutive patients with metastatic breast cancer treated with radiofrequency ablation (RFA) at the Department of Oncology, Herlev Hospital, University of Copenhagen, from 1996 to 2010.RESULTS: Time to intrahepatic progression was median 11 months (range 1.6-184 months). Median survival after first RFA was 33.5 months. Survival at 1, 2 and 3 years was 87, 68 and 48 %, respectively. The local recurrence rate was 22 %.CONCLUSIONS: In this small, highly selected cohort we found RFA safe and efficacious with a low local recurrence rate and a median survival above that expected with systemic treatment. Our data are in line with previous studies and underscore the need for a large prospective study using optimal chemotherapy regimens and RFA/surgery to clarify whether intense treatment protocols can prolong survival for certain patient groups.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Breast Neoplasms

KW - Catheter Ablation

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Liver Neoplasms

KW - Middle Aged

KW - Treatment Outcome

U2 - 10.1007/s11547-014-0489-6

DO - 10.1007/s11547-014-0489-6

M3 - Journal article

C2 - 25572543

SN - 0033-8362

VL - 120

SP - 536

EP - 541

JO - La Radiologia Medica

JF - La Radiologia Medica

IS - 6

ER -

Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this